Acute pericarditis in a patient with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a case report and review of the literature on SARS-CoV-2 cardiological manifestations.
Coronavirus disease 2019 (COVID-19)
cardiovascular manifestations
case report
pericarditis
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Journal
AME case reports
ISSN: 2523-1995
Titre abrégé: AME Case Rep
Pays: China
ID NLM: 101730832
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
05
2020
accepted:
13
11
2020
entrez:
26
2
2021
pubmed:
27
2
2021
medline:
27
2
2021
Statut:
epublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as coronavirus disease 2019 (COVID-19) is known to cause a cluster of flu-like illnesses and pneumonia with evolving understanding of other systemic manifestations. Currently, the known cardiac manifestations of COVID-19 include myocardial injury, acute coronary syndrome, and arrhythmias. In this report, we describe a case of pericarditis-an unusual cardiac manifestation observed in a patient with COVID-19. A 63-year-old male presented with history of fever, cough and chest pain. Electrocardiogram (EKG) demonstrated diffuse ST-T wave changes on all the leads, with normal troponin-T levels. Echocardiograph showed mild pericardial effusion without any regional wall motion abnormality. Subsequent chest radiograph and coronary angiography were normal. In view of ongoing COVID-19 pandemic, nasopharyngeal swab was performed, which was positive. Detailed etiological workup for pericarditis, including infectious and inflammatory causes were unremarkable. Viral pericarditis (possibly caused by COVID-19) was diagnosis of exclusion and patient was treated with hydroxychloroquine 200 mg twice a day, colchicine 0.5 mg twice a day, and lopinavir/ritonavir 200 mg/50 mg tablet twice a day for 10 days during admission. He was discharged with hydroxychloroquine 200 mg twice daily and colchicine 0.5 mg once daily for 15 days. On subsequent follow-up clinic visit, he reported resolution of symptoms. The purpose of this report is to add a potential cardiovascular complication of COVID-19 to the literature. Awareness of this manifestation can lead to timely laboratory and imaging examinations with potential to provide correct treatment and good outcome.
Identifiants
pubmed: 33634246
doi: 10.21037/acr-20-90
pii: acr-05-20-90
pmc: PMC7882268
doi:
Types de publication
Case Reports
Langues
eng
Pagination
6Informations de copyright
2021 AME Case Reports. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/acr-20-90). The authors have no conflicts of interest to declare.
Références
JAMA Cardiol. 2020 Jul 1;5(7):819-824
pubmed: 32219357
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
J Clin Virol. 2020 Jun;127:104366
pubmed: 32302954
Circulation. 2020 Jun 9;141(23):1930-1936
pubmed: 32243205
Eur Heart J. 2020 Jun 7;41(22):2130
pubmed: 32227076
JACC Case Rep. 2020 Jul 15;2(9):1326-1330
pubmed: 32328588
Nat Microbiol. 2020 Apr;5(4):562-569
pubmed: 32094589
Eur Heart J. 2020 May 14;41(19):1861-1862
pubmed: 32267502
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Front Med. 2020 Apr;14(2):185-192
pubmed: 32170560
Lancet Respir Med. 2020 Apr;8(4):e21
pubmed: 32171062
QJM. 2020 Jul 1;113(7):488-490
pubmed: 32311043
J Med Virol. 2020 Jul;92(7):819-823
pubmed: 32232979
Circ Res. 2016 Feb 5;118(3):496-514
pubmed: 26846643
JACC Heart Fail. 2020 Jun;8(6):515-517
pubmed: 32265149
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Eur Heart J. 2020 May 14;41(19):1859
pubmed: 32282027
Eur J Heart Fail. 2020 May;22(5):911-915
pubmed: 32275347
J Infect. 2020 Jun;80(6):639-645
pubmed: 32240670